2023
DOI: 10.1016/j.jacig.2023.100140
|View full text |Cite
|
Sign up to set email alerts
|

ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

Pedro Giavina-Bianchi,
Eric Cua,
Karine Risso
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 19 publications
0
1
0
Order By: Relevance
“…Obefazimod (ABX464) is a small molecule that up-regulates miR-124 in immune cells that reduces the production of inflammatory cytokines and prevents the proliferation of Th17 cells. However, once-daily oral obefazimod in a dose of 50 mg provided no benefit over placebo for severe COVID-19 in a randomized, double-blind placebo-controlled trial (miR-AGE) [66].…”
Section: Role Of Mirnas In Anti-infectious Immunitymentioning
confidence: 99%
“…Obefazimod (ABX464) is a small molecule that up-regulates miR-124 in immune cells that reduces the production of inflammatory cytokines and prevents the proliferation of Th17 cells. However, once-daily oral obefazimod in a dose of 50 mg provided no benefit over placebo for severe COVID-19 in a randomized, double-blind placebo-controlled trial (miR-AGE) [66].…”
Section: Role Of Mirnas In Anti-infectious Immunitymentioning
confidence: 99%